Company Filing History:
Years Active: 2001-2018
Title: Charles D. Leahy: Innovator in Ocular Drug Delivery
Introduction
Charles D. Leahy, a distinguished inventor based in Concord, MA, is known for his significant contributions to the field of ocular drug delivery systems. With a total of six patents to his name, he has made remarkable strides in developing innovative solutions aimed at combating myopia and enhancing patient care.
Latest Patents
Leahy's most recent patent showcases a device designed to deliver a sustained low dose of a myopia-suppressing drug while preserving pupillary function and accommodation. This non-degradable topical ocular drug delivery device features a complex of myopia-suppressing agents with an immobile acid, encapsulated within a crosslinked polymer matrix. This innovative configuration enables the controlled release of therapeutic agents over an extended period, effectively managing myopia progression.
Another notable patent involves an ocular device intended for insertion into the eye, designed with an anterior and posterior surface that corresponds with the curvature of the sclera. This device functions as an ocular drug delivery system, containing active pharmaceutical agents and lubricants to enhance its efficacy and patient comfort.
Career Highlights
Throughout his career, Charles D. Leahy has made impactful contributions, particularly through his work with innovative companies. He has collaborated with Vista Scientific LLC and Amorphex Therapeutics LLC, where he has been instrumental in transforming theoretical concepts into practical applications that benefit countless individuals affected by ocular conditions.
Collaborations
Throughout his journey, Leahy has worked alongside talented professionals such as Edward J. Ellis and Denis LaBombard. Together, they have enhanced the development of groundbreaking technologies in ocular healthcare.
Conclusion
Charles D. Leahy's visionary work in ocular drug delivery systems exemplifies the spirit of innovation and dedication to improving patient outcomes. With his expertise and collaborative efforts, he continues to pave the way for advancements in ophthalmology, making a lasting impact on the field.